Flexipharm Austrading Logo

Our first product was approved and made available to NHS hospitals in May 2019. Our portfolio will increase in 2019 and 2020.

We are proud to have an exceptional partner in Phebra Pty Ltd who have their own modern MHRA and FDA approved manufacturing facility which has ample capacity to supply UK demand. In addition, because of the mutual recognition agreements in place between the regulatory authorities of the UK and Australia supply of finished product into the UK from Australia, is straightforward and fast.

Arsenic Trioxide Phebra

Indicated for the treatment of low-intermediate risk acute promyelocytic leukaemia, this is a novel presentation of arsenic trioxide. The Summary of Product Characteristics can be found at https://www.medicines.org.uk/ emc/product/10278/smpc

Arsenic Trioxide Phebra is a generic product which offers several advantages to the NHS;

  1. Saves money. Arsenic Trioxide Phebra has an NHS price 7.7% less than equivalent arsenic trioxide ampoules; a pack of Arsenic Trioxide Phebra has an NHS price £220 less than the ampoule product1
  2. Saves time. Because it is a vial there is no need to use a filter needle/straw to draw up drug, this reduces the number of steps and time needed to make an infusion compared to using an ampoule
  3. Reduce risks. Vials are not associated with sharps injuries which are common from jagged edges or glass splinters from opening ampoules

References
1. https://bnf.nice.org.uk/medicinal-forms/arsenic-trioxide.html

© Flexipharm Austrading Ltd 2019
Privacy Policy
Cookies Policy